JP2016513097A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513097A5 JP2016513097A5 JP2015556938A JP2015556938A JP2016513097A5 JP 2016513097 A5 JP2016513097 A5 JP 2016513097A5 JP 2015556938 A JP2015556938 A JP 2015556938A JP 2015556938 A JP2015556938 A JP 2015556938A JP 2016513097 A5 JP2016513097 A5 JP 2016513097A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- albumin
- composition according
- paclitaxel
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 claims description 18
- 102000009027 Albumins Human genes 0.000 claims description 16
- 108010088751 Albumins Proteins 0.000 claims description 16
- 229930012538 Paclitaxel Natural products 0.000 claims description 16
- 229960001592 paclitaxel Drugs 0.000 claims description 16
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 16
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 8
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 229940125431 BRAF inhibitor Drugs 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 2
- 238000009093 first-line therapy Methods 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 208000021039 metastatic melanoma Diseases 0.000 claims description 2
- 238000009094 second-line therapy Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000003442 weekly effect Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 21
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361763391P | 2013-02-11 | 2013-02-11 | |
| US61/763,391 | 2013-02-11 | ||
| US13/791,841 | 2013-03-08 | ||
| US13/791,841 US9149455B2 (en) | 2012-11-09 | 2013-03-08 | Methods of treating melanoma |
| PCT/US2013/072877 WO2014123612A1 (en) | 2013-02-11 | 2013-12-03 | Methods of treating melanoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017214523A Division JP6470381B2 (ja) | 2013-02-11 | 2017-11-07 | メラノーマの治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513097A JP2016513097A (ja) | 2016-05-12 |
| JP2016513097A5 true JP2016513097A5 (enExample) | 2017-01-12 |
| JP6388880B2 JP6388880B2 (ja) | 2018-09-12 |
Family
ID=51300036
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556938A Active JP6388880B2 (ja) | 2013-02-11 | 2013-12-03 | メラノーマの治療方法 |
| JP2017214523A Active JP6470381B2 (ja) | 2013-02-11 | 2017-11-07 | メラノーマの治療方法 |
| JP2019006038A Withdrawn JP2019056014A (ja) | 2013-02-11 | 2019-01-17 | メラノーマの治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017214523A Active JP6470381B2 (ja) | 2013-02-11 | 2017-11-07 | メラノーマの治療方法 |
| JP2019006038A Withdrawn JP2019056014A (ja) | 2013-02-11 | 2019-01-17 | メラノーマの治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2953622B1 (enExample) |
| JP (3) | JP6388880B2 (enExample) |
| KR (1) | KR102148551B1 (enExample) |
| CN (2) | CN109200031A (enExample) |
| BR (1) | BR112015019064A8 (enExample) |
| CA (1) | CA2900668A1 (enExample) |
| ES (1) | ES2872328T3 (enExample) |
| HK (1) | HK1218506A1 (enExample) |
| IL (1) | IL240388B (enExample) |
| MX (1) | MX377729B (enExample) |
| NZ (1) | NZ630239A (enExample) |
| WO (1) | WO2014123612A1 (enExample) |
| ZA (1) | ZA201505956B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| US9393318B2 (en) | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| HUE048876T2 (hu) | 2011-05-09 | 2020-08-28 | Mayo Found Medical Education & Res | Rákos megbetegedések kezelése |
| PL2790675T3 (pl) | 2011-12-14 | 2019-12-31 | Abraxis Bioscience, Llc | Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek |
| US10413606B2 (en) | 2012-10-01 | 2019-09-17 | Mayo Foundation For Medical Education And Research | Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| JP6349381B2 (ja) | 2013-03-12 | 2018-06-27 | アブラクシス バイオサイエンス， エルエルシー | 肺がんを処置する方法 |
| JP6309610B2 (ja) | 2013-03-14 | 2018-04-11 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんを処置する方法 |
| WO2015095842A2 (en) | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| US10213513B2 (en) | 2014-06-16 | 2019-02-26 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| CN107073132B (zh) | 2014-10-06 | 2021-08-27 | 梅约医学教育与研究基金会 | 载体-抗体组合物及其制备和使用方法 |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| SMT202100642T1 (it) | 2015-06-29 | 2022-03-21 | Abraxis Bioscience Llc | Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| JP6921802B2 (ja) * | 2015-08-18 | 2021-08-18 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | キャリア結合剤組成物およびそれを作製および使用する方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| US11351254B2 (en) | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC |
| WO2017165440A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| CN109890419A (zh) * | 2016-09-01 | 2019-06-14 | 梅约医学教育与研究基金会 | 用于治疗癌症的载体-pd-l1结合剂组合物 |
| CN109843336A (zh) | 2016-09-01 | 2019-06-04 | 梅约医学教育与研究基金会 | 用于靶向t细胞癌症的方法和组合物 |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| AU2017324947A1 (en) | 2016-09-06 | 2019-03-28 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| CN109843924A (zh) | 2016-09-06 | 2019-06-04 | 梅约医学教育与研究基金会 | 治疗表达pd-l1的癌症的方法 |
| CA3076919A1 (en) * | 2017-10-03 | 2019-04-11 | Crititech, Inc. | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer |
| AU2019239953B2 (en) | 2018-03-20 | 2025-01-02 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| IL292439B2 (en) | 2019-10-28 | 2026-05-01 | Abraxis Bioscience Llc | Pharmaceutical preparations of albumin and rapamycin |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| CN103169729A (zh) * | 2005-02-18 | 2013-06-26 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CN101291658B (zh) | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | 用于制备稳定性增加的水难溶性药物的组合物和方法 |
| US20080045589A1 (en) * | 2006-05-26 | 2008-02-21 | Susan Kelley | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer |
| WO2008137148A2 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Methods and compositions for treating pulmonary hypertension |
| AU2009324464B2 (en) * | 2008-12-11 | 2016-05-05 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20130281376A1 (en) * | 2010-10-08 | 2013-10-24 | Abraxis Bioscience, Llc | Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer |
-
2013
- 2013-12-03 WO PCT/US2013/072877 patent/WO2014123612A1/en not_active Ceased
- 2013-12-03 MX MX2015010312A patent/MX377729B/es active IP Right Grant
- 2013-12-03 ES ES13874757T patent/ES2872328T3/es active Active
- 2013-12-03 CN CN201811025229.5A patent/CN109200031A/zh active Pending
- 2013-12-03 CN CN201380075292.9A patent/CN105120859B/zh active Active
- 2013-12-03 JP JP2015556938A patent/JP6388880B2/ja active Active
- 2013-12-03 HK HK16106468.2A patent/HK1218506A1/zh unknown
- 2013-12-03 CA CA2900668A patent/CA2900668A1/en not_active Abandoned
- 2013-12-03 NZ NZ630239A patent/NZ630239A/en unknown
- 2013-12-03 KR KR1020157024822A patent/KR102148551B1/ko active Active
- 2013-12-03 BR BR112015019064A patent/BR112015019064A8/pt not_active Application Discontinuation
- 2013-12-03 EP EP13874757.1A patent/EP2953622B1/en active Active
-
2015
- 2015-08-06 IL IL240388A patent/IL240388B/en active IP Right Grant
- 2015-08-18 ZA ZA2015/05956A patent/ZA201505956B/en unknown
-
2017
- 2017-11-07 JP JP2017214523A patent/JP6470381B2/ja active Active
-
2019
- 2019-01-17 JP JP2019006038A patent/JP2019056014A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523656A5 (enExample) | ||
| JP2016513075A5 (enExample) | ||
| Agarwal et al. | Do glucocorticoids decrease mortality in acute respiratory distress syndrome? A meta‐analysis | |
| JP2018111728A5 (enExample) | ||
| JP2016512513A5 (enExample) | ||
| JP2013503174A5 (enExample) | ||
| JP2016506908A5 (enExample) | ||
| JP2016512506A5 (enExample) | ||
| JP2012506448A5 (enExample) | ||
| JP2010509331A5 (enExample) | ||
| NZ604029A (en) | Methods of treating bladder cancer | |
| JP2017226708A5 (enExample) | ||
| JP2010514787A5 (enExample) | ||
| MX2019013701A (es) | Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos. | |
| JP2011511072A5 (enExample) | ||
| JP2017503842A5 (enExample) | ||
| EA200701195A1 (ru) | Содержащие цефалоспорин композиции с наночастицами и с контролируемым высвобождением | |
| JP2016515586A5 (enExample) | ||
| JP2013527233A5 (enExample) | ||
| JP2019507797A5 (enExample) | ||
| HRP20160609T1 (hr) | Postupci liječenja hepatocelularnog karcinoma | |
| HRP20250141T1 (hr) | Nanočestice koje sadrže sirolimus i albumin za upotrebu u liječenju tumora epiteloidnih stanica | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2019522032A5 (enExample) |